Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 11, 2024 (filed on Mar 11, 2024)Insider Name:Krishnan SumaOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,254Price:$168.88
-
Mar 11, 2024 (filed on Mar 11, 2024)Insider Name:Krishnan SumaOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,146Price:$167.99
-
Mar 11, 2024 (filed on Mar 11, 2024)Insider Name:Krishnan SumaOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-800Price:$174.13
-
Mar 11, 2024 (filed on Mar 11, 2024)Insider Name:Krishnan SumaOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-3,587Price:$173.30
-
Mar 11, 2024 (filed on Mar 11, 2024)Insider Name:Krishnan SumaOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,800Price:$172.21
-
Mar 11, 2024 (filed on Mar 11, 2024)Insider Name:Krishnan SumaOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-5,469Price:$171.09
-
Mar 11, 2024 (filed on Mar 11, 2024)Insider Name:Krishnan SumaOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-8,040Price:$170.42
-
Mar 11, 2024 (filed on Mar 11, 2024)Insider Name:Krishnan SumaOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,646Price:$168.96
-
Mar 11, 2024 (filed on Mar 11, 2024)Insider Name:Krishnan SumaOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,314Price:$174.00
-
Mar 11, 2024 (filed on Mar 11, 2024)Insider Name:Krishnan SumaOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-3,359Price:$173.09
Filings by filing date
-
Mar 11, 2024 (filed on Mar 11, 2024)Insider Name:Krishnan SumaOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,254Price:$168.88
-
Mar 11, 2024 (filed on Mar 11, 2024)Insider Name:Krishnan SumaOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,146Price:$167.99
-
Mar 11, 2024 (filed on Mar 11, 2024)Insider Name:Krishnan SumaOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-800Price:$174.13
-
Mar 11, 2024 (filed on Mar 11, 2024)Insider Name:Krishnan SumaOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-3,587Price:$173.30
-
Mar 11, 2024 (filed on Mar 11, 2024)Insider Name:Krishnan SumaOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,800Price:$172.21
-
Mar 11, 2024 (filed on Mar 11, 2024)Insider Name:Krishnan SumaOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-5,469Price:$171.09
-
Mar 11, 2024 (filed on Mar 11, 2024)Insider Name:Krishnan SumaOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-8,040Price:$170.42
-
Mar 11, 2024 (filed on Mar 11, 2024)Insider Name:Krishnan SumaOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,646Price:$168.96
-
Mar 11, 2024 (filed on Mar 11, 2024)Insider Name:Krishnan SumaOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,314Price:$174.00
-
Mar 11, 2024 (filed on Mar 11, 2024)Insider Name:Krishnan SumaOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-3,359Price:$173.09
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 2100 Wharton St Ste 701 PITTSBURGH PA 15203-1973 |
Tel: | N/A |
Website: | https://www.krystalbio.com |
IR: | See website |
Key People | ||
Krish S. Krishnan Chairman of the Board, President, Chief Executive Officer | Suma M. Krishnan Founder, Chief Operating Officer, Director, President - Research and Development | Kathryn A. Romano Chief Accounting Officer |
Business Overview |
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. It is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include VYJUVEK, KB407, KB408, KB707, KB105, KB104, KB104, and KB301. Its commercial product VYJUVEK is a non-invasive, topical, redo sable gene therapy designed to deliver two copies of theCOL7A1 gene when applied directly to DEB wounds. VYJUVEK is designed to treat DEB at the molecular level by providing the patient's skin cells the template to make normal COL7 protein, thereby addressing the fundamental disease-causing mechanism. KB407 is developed for the treatment of Cystic Fibrosis. KB408 is developed for the treatment of Alpha-1 Antitrypsin Deficiency. KB707 is developed for the treatment of solid tumors. KB105 is developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. |
Financial Overview |
For the fiscal year ended 31 December 2023, Krystal Biotech Inc revenues increased from $0K to $50.7M. Net income totaled $10.9M vs. loss of $140M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Pharmaceuticals segment loss decrease of 24% to $109.7M. Basic Earnings per Share excluding Extraordinary Items increased from -$5.49 to $0.40. |
Employees: | 229 as of Feb 19, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $4,143M as of Dec 31, 2023 |
Annual revenue (TTM): | $50.70M as of Dec 31, 2023 |
EBITDA (TTM): | -$91.29M as of Dec 31, 2023 |
Net annual income (TTM): | $10.93M as of Dec 31, 2023 |
Free cash flow (TTM): | -$100.60M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 28,514,547 as of Mar 25, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |